Research indicates TRL and Lp(a) contribute to heart disease beyond LDL levels — Evidence Review
Published by researchers at Chalmers University of Technology
Researched by
— the AI search engine for science
Table of Contents
Researchers at Chalmers University of Technology have identified biological processes involving triglyceride-rich lipoproteins (TRL) and lipoprotein(a) [Lp(a)] that may explain why some individuals develop heart disease despite having low LDL ("bad cholesterol") levels. Related studies generally support the notion that TRL and Lp(a) contribute to residual cardiovascular risk beyond traditional cholesterol measures.
- Several large meta-analyses and consensus statements have previously established that elevated Lp(a) and TRL/remnants independently increase the risk of coronary heart disease (CHD), even after LDL is lowered 1 2 3 4 5 8 9.
- The new study adds mechanistic insight by using proteomics to show that TRL and Lp(a) may promote inflammation and vascular changes in similar ways, complementing earlier epidemiological and genetic research that identified these particles as risk factors 2 4 5 8 9.
- Existing literature emphasizes that standard lipid-lowering therapies have limited impact on Lp(a) and TRL, supporting the need for novel prevention strategies as highlighted by the current findings 4 5 9.
Study Overview and Key Findings
Heart disease remains the leading cause of death worldwide, and lowering LDL cholesterol is a proven method to reduce heart attack risk. However, a notable number of individuals still experience cardiovascular events despite achieving recommended LDL levels. This study is significant as it investigates the biological mechanisms behind this residual risk, specifically focusing on the roles of different fat-carrying particles in the blood. By applying proteomics analysis, the researchers examined how LDL, TRL, and Lp(a) may independently contribute to cardiovascular disease, moving beyond the traditional cholesterol-centric view.
| Property | Value |
|---|---|
| Organization | Chalmers University of Technology |
| Authors | Jakub Morze |
| Population | Not specified |
| Sample Size | nearly 3,000 proteins |
| Outcome | Biological processes contributing to heart disease risk |
| Results | TRL and Lp(a) may contribute to heart disease beyond LDL levels |
Literature Review: Related Studies
To assess the broader context of these findings, we searched the Consensus database, which includes over 200 million research papers. The following search queries were used:
- heart disease TRL Lp(a) connection
- low LDL heart attack risk factors
- cholesterol levels heart attack mechanisms
| Topic | Key Findings |
|---|---|
| What explains heart disease risk when LDL cholesterol is low? | - Elevated TRL and Lp(a) levels are linked to residual cardiovascular risk even after LDL-C reduction, indicating other lipid parameters contribute to heart disease 1 2 4 5 8 9. - Inflammation and particle number (apoB-containing lipoproteins) may mediate this remaining risk 8 9. |
| How do TRL and Lp(a) contribute to cardiovascular disease? | - TRL and remnants have pleiotropic proatherogenic actions, including promoting inflammation, endothelial dysfunction, and cholesterol deposition, contributing to atherosclerosis 2 8 9. - Lp(a) is a heritable, independent causal risk factor, especially through vascular inflammation and thrombogenicity 1 4 5. |
| Are there effective therapies for TRL and Lp(a)-mediated risk? | - Standard LDL-lowering therapies (e.g., statins, ezetimibe) have little effect on Lp(a) and modest effect on TRL; new approaches like antisense oligonucleotides for Lp(a) and therapies targeting TRL production/removal are under investigation 4 5 9. - Residual cardiovascular risk persists despite optimized LDL-C therapy, highlighting the need for new treatments targeting TRL, Lp(a), and inflammation 2 4 5 9. |
| What is the role of cumulative and lifelong LDL exposure? | - Cumulative LDL-C exposure is a major predictor of lifetime CHD risk, and lowering LDL at younger ages is associated with the greatest long-term benefit 7 10 11 12 13 14 15. - Even at "normal" cholesterol levels, genetic susceptibility or other risk factors (e.g., Lp(a), VLDL) may lead to atherosclerosis 7 10 12 15. |
What explains heart disease risk when LDL cholesterol is low?
A growing body of research demonstrates that residual cardiovascular risk persists in individuals who achieve low LDL cholesterol, implicating other lipoprotein particles and inflammatory processes. The new study's focus on TRL and Lp(a) aligns with these findings, as both have been identified as contributors to risk in individuals with well-controlled LDL.
- Multiple studies show that high TRL and Lp(a) levels are associated with increased risk of coronary heart disease and stroke, even after LDL-C is lowered 1 2 4 5 8 9.
- Additional biomarkers, including C-reactive protein (a marker of inflammation), can further stratify residual risk 9.
- The new study's proteomics approach provides mechanistic evidence that TRL and Lp(a) may drive risk through shared inflammatory pathways, not just cholesterol deposition 9.
- These findings reinforce that measuring and targeting only LDL cholesterol may not fully capture or address cardiovascular risk 8 9.
How do TRL and Lp(a) contribute to cardiovascular disease?
Evidence from genetic, epidemiological, and mechanistic studies supports the role of TRL and Lp(a) in atherosclerosis through multiple mechanisms beyond cholesterol transport. The current study adds that TRL and Lp(a) share proteomic signatures linked to inflammation and vascular remodeling, deepening our understanding of their proatherogenic actions.
- TRL and remnants promote arterial wall inflammation, endothelial dysfunction, and cholesterol accumulation, all contributing to atherosclerosis 2 8 9.
- Lp(a) is particularly implicated in vascular inflammation, thrombosis, and calcification, increasing risk for both CHD and aortic valve stenosis 1 4 5.
- The proteomic overlap between TRL and Lp(a) may suggest common therapeutic targets for reducing inflammation-driven cardiovascular risk 2 4.
- Genetic studies support a causal relationship between elevated Lp(a)/TRL and increased cardiovascular events 1 4 5.
Are there effective therapies for TRL and Lp(a)-mediated risk?
Current cholesterol-lowering therapies are effective at reducing LDL-C but have limited impact on TRL and Lp(a) levels. The need for novel treatments is widely recognized, and new agents targeting these particles are in development or early clinical trials.
- Statins and ezetimibe reduce LDL but minimally affect Lp(a); proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors modestly reduce Lp(a) 4 5 9.
- Antisense oligonucleotides and small interfering RNAs show promise for potent Lp(a) lowering and are being evaluated in clinical trials 4 5.
- Therapies that target TRL production, lipolysis, or hepatic clearance are being explored, as TRL remain a significant source of residual risk 2 4 9.
- Persistent risk after LDL-C lowering underscores the need for new preventive and therapeutic approaches 2 5 9.
What is the role of cumulative and lifelong LDL exposure?
While the new study highlights risk beyond LDL, extensive evidence confirms that the cumulative burden of LDL-C remains a central determinant of cardiovascular disease. Lifelong exposure and genetic susceptibility play key roles, and early intervention yields the greatest risk reduction.
- Long-term and cumulative LDL-C exposure, especially from young adulthood, is strongly associated with increased risk of CHD, independent of midlife LDL levels 7 10.
- Genetic studies confirm that populations with lifelong low LDL-C have lower rates of atherosclerosis, supporting the "lower is better" paradigm 11 12 15.
- Individuals with "normal" LDL-C may still be at risk due to genetic or other factors such as high Lp(a), VLDL, or inflammatory burden 7 10 12 15.
- The new findings complement, rather than contradict, the established importance of LDL, suggesting that both LDL-C and other atherogenic particles should be managed for optimal prevention 7 10 12 15.
Future Research Questions
Further research is needed to determine whether interventions targeting TRL, Lp(a), or their associated inflammatory pathways can reduce cardiovascular risk beyond current therapies. Large-scale clinical trials and biomarker studies are necessary to guide future prevention strategies and clarify the clinical utility of proteomic profiling.
| Research Question | Relevance |
|---|---|
| Does targeting TRL or Lp(a) with novel therapies reduce cardiovascular events beyond LDL lowering? | As current treatments have limited impact on these particles, clinical trials are needed to establish whether their reduction translates to lower cardiovascular event rates 4 5 9. |
| Can proteomic signatures of TRL and Lp(a) predict individual cardiovascular risk? | The new study suggests proteomic patterns may identify at-risk patients; validating these biomarkers could improve risk stratification and personalized prevention 2 8 9. |
| What are the mechanistic pathways linking TRL and Lp(a) to vascular inflammation and atherosclerosis? | Deeper mechanistic understanding may reveal new drug targets and clarify how these particles promote cardiovascular disease 2 4 5. |
| How should TRL and Lp(a) be incorporated into clinical risk assessment algorithms? | Incorporating these factors into guidelines could improve risk prediction and guide therapy, but evidence from outcome studies is needed 3 5 8 9. |
| What are the long-term effects of combining LDL lowering with TRL and Lp(a) modification? | Studying combination strategies will clarify if multi-targeted lipid management offers additive or synergistic benefits for cardiovascular prevention 2 5 9. |